Abbott Laboratories (ABT) EBT (2016 - 2026)

Abbott Laboratories' EBT history spans 18 years, with the latest figure at $1.4 billion for Q1 2026.

On a quarterly basis, EBT fell 18.5% to $1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $8.1 billion, a 10.63% increase, with the full-year FY2025 number at $8.5 billion, up 20.72% from a year prior.
EBT hit $1.4 billion in Q1 2026 for Abbott Laboratories, down from $2.4 billion in the prior quarter.
Over the last five years, EBT for ABT hit a ceiling of $2.9 billion in Q1 2022 and a floor of $1.3 billion in Q4 2022.
Historically, EBT has averaged $1.9 billion across 5 years, with a median of $1.8 billion in 2025.
Biggest five-year swings in EBT: surged 74.48% in 2022 and later tumbled 45.69% in 2023.
Tracing ABT's EBT over 5 years: stood at $1.3 billion in 2022, then surged by 35.98% to $1.8 billion in 2023, then grew by 13.09% to $2.0 billion in 2024, then rose by 16.16% to $2.4 billion in 2025, then tumbled by 38.55% to $1.4 billion in 2026.
Business Quant data shows EBT for ABT at $1.4 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.2 billion in Q3 2025.

Peer Comparison